羊膜及其制品在宫腔粘连治疗中的有效性及安全性研究进展  

Research progress on the effectiveness and safety of amniotic membrane and its products in the treatment of intrauterine adhesions

作　　者：祝鑫瑜(综述)[1] 张云鹤(审校) ZHU Xin-yu;ZHANG Yun-he(Department of Obstetrics and Gynecology,Beijing Municipality Corps Hospital of PAP,Beijing 100027,China)

机构地区：[1]武警北京总队医院妇产科,北京100027 [2]煤炭总医院妇产科,北京100028

出　　处：《武警后勤学院学报（医学版）》2019年第7期81-84,共4页Journal of Logistics University of PAP（Medical Sciences）

基　　金：煤炭总医院医学发展科研基金项目(K201618)

摘　　要：宫腔镜下宫腔粘连分离术(transcervical resection of adhesions,TCRA)是治疗宫腔粘连的规范术式,在无防粘连的措施下,术后再粘连率较高。因羊膜具有调控细胞分化、分泌多种生物活性因子、改善微环境、抑制炎症反应、抗纤维化,且含有干细胞样细胞等特性,学者们开始使用新鲜羊膜及与其生物学活性相似的冻干羊膜制品,用以预防宫腔再粘连。现就羊膜及其制品在宫腔粘连分离术中应用的安全性及有效性综述如下。Trans-cervical resection of adhesions(TCRA) is now recognized as the standard method for the treatment of IUA. In the absence of anti-adhesion measures, the rate of re-adhesion after operation is very high. Because amniotic membrane can regulate cell differentiation, secrete a variety of bioactive factors, improve the micro environment, inhibit inflammation and fibrosis, and contain stem cells and so on, researchers began to use fresh amniotic membrane and its freeze-dried products which are similar to fresh amnion in morphology and biological activity for patients with severe IUA to prevent re-adhesion. The safety and effectiveness of amniotic membrane and its products in TCRA are reviewed as follows.

关 键 词：羊膜 宫腔粘连 进展 

分 类 号：R711[医药卫生—妇产科学]